Lunai Bioworks Inc. (LNAI) stock
Close on Oct 28, 2026Market cap –P/E –Yield –
Lunai Bioworks Inc. reported revenue of $51.99K for the twelve months to Jun 30, 2026. Free cash flow was -$5.29M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $51.99K
- Net income
- -$3.56M
- EPS, diluted
- -$1.06
- Free cash flow
- -$5.29M
Trading
- Previous close
- $0.25
- Open
- $0.22
- Day's range
- $0.20 – $0.25
- Volume
- 622,775
- Average volume (20 days)
- 676,122
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 28, 2026. The S&P 500 is measured by the SPY fund.
| Period | LNAI | S&P 500 | Difference | LNAI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -87.1% | +0.9% | −88.0 pts | ||
| 3 months | -89.3% | +4.5% | −93.8 pts | ||
| Year to date | -96.6% | +14.1% | −110.7 pts | ||
| 1 year | -97.1% | +13.6% | −110.7 pts | ||
| 3 years | -99.9% | +95.0% | −194.9 pts | -89.7% | +24.9% |
| 5 years | -100.0% | +80.2% | −180.1 pts | -79.8% | +12.5% |
Thirteen years at a glance
Fiscal years 2011 to 2026, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Lunai Bioworks filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- News
- News
- News
- Update
About Lunai Bioworks
Pharmaceutical Preparations
Lunai Bioworks Inc. is an artificial intelligence-driven biotechnology company that focuses on precision medicine, biomarker discovery, and therapy development for central nervous system disorders, biodefense, and severe diseases with unmet needs. The company functions primarily through two operating segments: Renovaro Biosciences and BioSymetrics. Renovaro Biosciences develops allogeneic cell and gene therapy candidates, focusing on genetically modified dendritic cell therapeutic vaccines targeting solid tumors like pancreatic and triple-negative breast cancers. BioSymetrics operates a biomedical artificial intelligence platform that combines multimodal biological data, proprietary machine learning models, and phenotypic knowledge graphs with experimental validation. The company collaborates with pharmaceutical enterprises, academic organizations, and healthcare providers to develop research programs and analytical discovery tools.
Company profile, executives and historyLunai Bioworks stock: common questions
What is Lunai Bioworks's stock price?
LNAI closed at $0.24 on Oct 28, 2026, down 4.00% on the day.
What is LNAI's P/E ratio?
Lunai Bioworks lost money over fiscal 2026 (diluted EPS -$1.06), so it has no meaningful P/E ratio.
How much revenue does Lunai Bioworks make?
Lunai Bioworks reported revenue of $51.99K for the twelve months to Jun 30, 2026.
Does Lunai Bioworks pay a dividend?
No. Lunai Bioworks has not paid a cash dividend over the last twelve months.
How has LNAI stock performed over the past year?
Including dividends, LNAI returned -97.1% over the past year, against +13.6% for the S&P 500.
Who are Lunai Bioworks's competitors?
Companies most similar to Lunai Bioworks by business, industry and size include IBO, KZIA, NTHI, SILO, SNGX.
See a number that looks wrong?